Retrospective cohort analysis examines GLP-1 therapy effects on cardiovascular and renal outcomes in type 1 diabetes, suggesting positive implications.
Key Points
This analysis aims to explore the impact of GLP-1-based therapy on cardiovascular and renal outcomes in adults with type 1 diabetes.
Retrospective cohort study utilizing the TriNetX global health research network.
Adults with type 1 diabetes were classified by exposure to GLP-1 therapy and matched on baseline characteristics.
Outcomes included all-cause mortality, various cardiovascular events, and safety outcomes.
GLP-1 therapy was linked to reduced all-cause mortality (HR 0.67, 95% CI 0.46-0.98) and heart failure (HR 0.38, 95% CI 0.21-0.67).
Adapted major adverse cardiovascular events were also lower (HR 0.61, 95% CI 0.40-0.94) along with decreased all-cause hospitalization (HR 0.70, 95% CI 0.51-0.96).
Hypoglycemia risk was lower (HR 0.72, 95% CI 0.55-0.95) without increased diabetic ketoacidosis incidence.